Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients

Aaltonen Panu, Carpén Olli, Mustonen Harri, Puolakkainen Pauli, Haglund Caj, Peltola Katriina, Seppänen Hanna

PII: S0748-7983(21)00925-2
DOI: https://doi.org/10.1016/j.ejso.2021.11.116
Reference: YEJSO 6420

To appear in: European Journal of Surgical Oncology

Received Date: 31 May 2021
Revised Date: 9 November 2021
Accepted Date: 15 November 2021

Please cite this article as: Panu A, Olli Carpé, Harri M, Pauli P, Caj H, Katriina P, Hanna Seppä, Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients, European Journal of Surgical Oncology (2021), doi: https://doi.org/10.1016/j.ejso.2021.11.116.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Ltd.
Aaltonen P: Data Curation, Formal analysis, Writing - Original Draft
Carpén O: Conceptualization, Writing - Review & Editing
Mustonen H: Formal analysis, Writing - Review & Editing
Puolakkainen P: Supervision, Writing - Review & Editing
Haglund C: Conceptualization, Writing - Review & Editing
Peltola K: Resources, Writing - Review & Editing
Seppänen H: Supervision, Project administration, Writing - Review & Editing
Title: Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients

Author names (family name first): Aaltonen Panu¹, Carpén Olli (olli.carpen@helsinki.fi)², Mustonen Harri (harri.mustonen@helsinki.fi)¹, Puolakkainen Pauli (pauli.puolakkainen@hus.fi)¹, Haglund Caj (caj.haglund@hus.fi)³, Peltola Katriina (katriina.peltola@hus.fi)³, Seppänen Hanna (hanna.seppanen@hus.fi)³

Affiliations:
¹Department of Surgery, Translational Cancer Medicine Research Programme, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
²Medicum, Research Programme in Systems Oncology and HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
³Comprehensive Cancer Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Corresponding author:
Panu Aaltonen
Helsinki University Hospital
PL 340, 00029, Finland
tel: +358504302101
panu.aaltonen@hus.fi

Submission category: Original research article
ABSTRACT

Whilst treatment modalities for pancreatic cancer patients have evolved in recent years, their impact on outcomes remains relatively unexamined on a national scale. We aimed to analyse changes in overall survival and trends in surgical and oncological treatments in pancreatic cancer patients diagnosed in the periods 2000 through 2008 and 2009 through 2016 in Finland. We collected data for pancreatic cancer patients diagnosed between 2000 and 2016, gathering data from the Finnish national registries on surgeries, oncological treatments and time of death. Follow-up continued through the end of 2018. We compared patients diagnosed between 2000 and 2008 to those diagnosed between 2009 through 2016. Our study comprised 14,712 pancreatic cancer patients. There was no significant change in the national resection rate (8.1% vs 8.0%, p = 0.690). In radical surgery patients, median survival improved from 20 months (95% confidence interval (CI) 18–22) to 28 months (CI 25–31) (p < 0.001), with 1-year survival ranging from 70% to 81%. In the no-surgery group, median survival slightly improved from 3.1 months (CI 3.0–3.3) to 3.3 months (CI 3.1–3.4) (p < 0.001). The proportion of radical surgery patients receiving preoperative oncological treatment increased from 4% to 13% (p < 0.001) and only postoperative treatment from 25% to 47% (p < 0.001). Whilst the resection rate did not increase, the prognosis of pancreatic cancer patients improved, particularly amongst radical surgery patients resulting most likely from the fact that a larger proportion of patients receive more effective oncological treatments.
Keywords: pancreatic cancer, epidemiology, survival, nationwide

Abbreviations:

95% confidence interval (CI)
International Classification of Diseases Version 10 (ICD-10)
Care Register for Health Care (HILMO)
Year (y)
Median (Mdn)
Hazard ratio (HR)
Charlson Comorbidity Index (CCI)
Pancreaticoduodenectomy (PD)
Distal pancreatic resection (DPR)
Total pancreatectomy (TP)
1. Introduction

Finland has a population of 5.5 million and the public healthcare system cares for the large majority of pancreatic cancer patients, with no pancreatic surgery performed in the private sector. Finland has high-quality national registers providing comprehensive information about Finnish pancreatic cancer patients.[1–3] As a quality indicator of the Finnish Cancer Registry, in 2018 93.6% of all cancer cases were microscopically verified. [2] Reporting to the Finnish Cancer Registry is mandated by legislation.

In Finland, five university hospitals are situated in Helsinki, Turku, Tampere, Kuopio and Oulu. For each of these university hospitals, Finland is divided into five specific catchment areas which are further divided into a total of 21 healthcare districts. The centralisation of pancreatic surgery has reportedly improved resection rates and survival.[4,5] Although some trend towards the centralisation of pancreatic cancer surgery to Finland’s five university hospitals has emerged during the 2000s the legislation was not enacted until 2018. Pancreatic cancer is a gastrointestinal malignancy with an especially poor prognosis.[6,7] The annual incidence of pancreatic cancer in Finland has increased from 19 per 100 000 in 2000 to 24 per 100 000 in 2016, which is high compared to estimates for the European incidence of 10 per 100 000.[8,9] Pancreatic cancer is most often diagnosed at an advanced stage partially due to late presenting symptoms.[10] Overall prognosis remains poor, although minor improvements have been reported in population-based studies.[6,11] In the global Concord-3 register study, the 5-year survival of Finnish pancreatic cancer patients improved from 4.1% in 2000–2004 to 7.4% in 2010–2014.[6] Radical resection, as a part of multimodal therapy, represents the only known potentially curative treatment.[12]

The aim of this study was to investigate changes in the treatment of and survival amongst pancreatic cancer patients in Finland between 2000 and 2016. The hypothesis was that the proportion of patients undergoing radical intent treatment would have increased and survival would have
improved due to advancements in the treatment of pancreatic cancer in recent decades. [12–15]

Neoadjuvant therapy plays an increasing role in the treatment of borderline and particularly locally advanced cases. [13,14,16–18]
2. **Material and methods** Patients diagnosed with pancreatic cancer (ICD-10 code: C25) between 2000 and 2016 were identified from the Finnish Cancer Registry. In 71% of patients, data on stage was available in the registry but as it was inconsistently classified and has been reported to be partly unreliable, it was not included in the analysis.[19] Residence as well as time and cause of death were collected from Statistics Finland. Patients’ healthcare visits were collected from the Care Register for Health Care (HILMO) from the National Institute for Health and Welfare. The Care Register includes nationwide data on patients discharged from inpatient care, day surgeries and specialised outpatient care. The completeness of the source data has been evaluated to be excellent especially regarding inpatient data and thus data on pancreatic surgeries. [1] Treatment periods including surgery were identified based on the Nordic Classification of Surgical Procedures. Charlson comorbidity index (CCI) was collected based on healthcare visits prior to pancreatic cancer diagnosis.[20–22] Patients with a diagnosis of a neuroendocrine tumour (ICD-10 code C25.4) or pancreatic tumour enucleation procedure were excluded (n = 189). Patients younger than 18 years old at diagnosis were excluded (n = 3). Cases in which the method of diagnosis was death certificate only (n=740) or autopsy (n=1781) were excluded since the duration of survival is unknown. [23]

To investigate changes in treatment and survival, we divided patients into two groups based on the period during which they received their diagnosis: 2000–2008 and 2009–2016. We calculated overall survival, and censored patients still living as of 31 December 2018.

Radical surgeries consisted of pancreaticoduodenectomy, distal pancreatic resection, total pancreatectomy and unspecified pancreatic resections. In our analysis, we grouped open and minimally invasive operations together. Postoperative mortality was calculated at 30 days and at 90 days following surgery. Patients undergoing elective explorative or biliodigestive bypass procedures, but not radical pancreatic surgery, were identified as representing a patient group treated with radical intent but were identified as non-resectable. We labelled this group as diagnostic surgeries. On-call procedures were not included.
Chemo- and radiation therapy were identified from the HILMO data for the pancreatic cancer treatment periods using oncological treatment procedure codes (Nordic Classification of Surgical Procedures). Whilst the coverage of oncological treatment data in HILMO was unknown, we collected local patient register data from the Helsinki University Central Hospital area and compared the two datasets. It was found that 85% of patients who had oncological treatment based on the local register data had it also based on the HILMO data. Datasets were then combined. By comparing the dates of the oncological treatments and that for surgery, we determined whether the oncological treatment was only preoperative, only postoperative or perioperative for patients that underwent surgery. Information about specific chemotherapy agents was not available.

Data were analysed in three groups based on the surgical treatment: radical surgery, diagnostic surgery and no surgery. Based on the oncological treatment, we further divided the data into the following subgroups: perioperative, only preoperative, only postoperative and no oncological treatment in the radical surgery group; preoperative, only postoperative and no oncological treatment in the diagnostic surgery group; and any and no oncological treatment in the no-surgery group.

In this study, patients were divided into the specific catchment areas, Helsinki, Turku, Tampere, Kuopio and Oulu, according to their home municipality during the year of their diagnosis. We then compared regional differences between these five specific catchment areas.

We performed all statistical analyses using IBM’s SPSS Statistics for Windows, version 27.0.1 (Armonk, NY: IBM Corp). Changes in treatment groups were evaluated using the Fisher’s exact test or the chi-square test. Survival amongst different groups was analysed using the Kaplan-Meier method, whereby we compared differences using the log-rank test. The Bonferroni method was used for multiple comparisons requiring adjusted $P$ values.

Cox regression was used for a multivariate analysis of radically operated patients. In 112 patients the delay of starting postoperative oncological treatment after radical surgery was more the 6 months
and this was thought to represent palliative treatment of recurrent disease. These patients were censored at 6 months from radical surgery in the multivariable analysis. Six patients were excluded for the multivariate analysis because they had preoperative oncological therapy started over 12 months before the radical operation. Immortal time bias was corrected for oncological treatments by using time dependent variables to classify the patients to different oncological treatment groups in timely manner. For neoadjuvant treatment group the time of classification was at surgery date and for the adjuvant group the beginning of the adjuvant treatment. In patients undergoing perioperative treatment, we estimated the period from surgery to adjuvant treatment from the adjuvant treatment group (median time). Since the cox assumption of constant hazard ratio (HR) over time was not fulfilled for adjuvant and perioperative treatments, a time dependent variable was added. Interactions were considered, but no significant interaction were found after Bonferroni correction for multiple testing. The follow-up time was restricted to nine years for the cox regression analyses. We considered $p < 0.05$ statistically significant applying two-tailed tests.

The National Institute for Health and Welfare (THL/1255/5.05.00/2018), Statistics Finland (TK-52-832-19) and the Helsinki University Hospital (§ 91 HUS/419/2018) approved the study protocol.
3. Results

In total, our study comprised 14,712 patients, amongst whom 6903 (47%) were male and 7809 (53%) female (Table 1). The median age was 73 years (range 19–103). There were 6702 (46%) patients diagnosed in 2000–2008 and 8010 (54%) patients diagnosed in 2009–2016. The median age for each period was 73 (range 21–103) and 73 (range 19–102) years, respectively. The distribution of patients across specific catchment areas was as follows: 4740 (32%) patients in Helsinki, 2985 (20%) in Tampere, 2507 (17%) in Turku, 2359 (16%) in Kuopio and 2045 (14%) in Oulu.

Method of diagnosis was histology of primary tumour or metastasis in 47% (n=4967), cytology in 14% (n=14) and clinical, including radiological imaging and specific tumour markers in 39% (n=5720). In 99% (n=1066) of patients who underwent radical surgery, the diagnosis was confirmed by histology. Comparing 2000–2008 and 2009–2016 there were 1132 vs 649 cases diagnosed with autopsy (p < 0.001) and 402 vs 338 patients with death certificate only (p < 0.001) that were excluded from further analyses.

Comparing the time periods 2000–2008 and 2009–2016 by the Charlson comorbidity index at the time of diagnosis, there were 60% (n=4010) vs 43% (n=3431) patients with a score of 0, 20% (n=1319) vs 22% (n=1742) with a score of 1, 12% (n=822) vs 17% (n=1381) with a score of 2 and 8% (n=551) vs 18% (n=1456) with a score of 3 or more, p < 0.001. In the radical surgery group, there were 68% (n=369) vs 51% (n=326) with a score of 0, 19% (n=103) vs 20% (n=125) with a score of 1, 9% (n=50) vs 17% (107) with a score of 2 and 4% (n=23) vs 12% (n=79) with a score of 3 or more, p < 0.001. Prevalence of specific comorbidities among patients at the time of diagnosis is provided in the Supplementary Table 1.

A total of 1182 (8.0%) patients underwent radical surgery for pancreatic cancer. Radical surgeries consisted of pancreaticoduodenectomy in 951 (81%) patients, distal pancreatic resection in 145 (12%), total pancreatectomy in 65 (6%) and unspecified pancreatic resection in 21 (2%). Annual resection rate ranged from 6.3% (n=47) in 2004 to 11.4% (n=120) in 2016. We detected no
significant change in the resection rate for any region when comparing the time periods 2000–2008 and 2009–2016.

In the radical surgery group, 30-day mortality was 1.9% (n=22) and climbing to 3.3% (n=39) for 90-day mortality. The 30-day mortality did not significantly change, from 1.7% (n=9) in 2000–2008 and 2.0% (n=13) in 2009–2016 (p = 0.671). The 90-day mortality also did not significantly change, reaching 3.5% (n=19) in 2000–2008 falling to 3.1% (n=20) in 2009–2016 (p = 0.740).

In diagnostic surgery group, 42% (n=235) vs 42% (n=131) patients underwent elective biliodigestive bypass and 58% (n=325) vs 58% (n=184) only elective explorative surgery. There were 12,676 patients (86%) who did not undergo elective surgery for pancreatic cancer.

A total of 3,257 (21%) patients received oncological treatment for pancreatic cancer. Twenty percent (n=3,001) received chemotherapy and 3.3% (n=486) radiation. Comparing 2000–2008 and 2009–2016, we observed a significant increase in the proportions receiving oncological treatment from 13% (n=848) to 29% (n=2,286) (p< 0.001). Likewise, there were significant increases in the proportions of patients receiving chemotherapy (12% vs 27%, p < 0.001) and radiation (1.6% vs 4.7%, p < 0.001).

In the radical surgery group, the proportion of patients receiving oncologic treatment increased from 30% (n=162) to 60% (n=385) (Table 1). Amongst patients who received preoperative treatment before radical surgery (n = 109), 79% (n = 86) also received postoperative treatment. In the radical surgery group, 8% (n=96) of patients received radiation therapy. Overall, 13% (n=56) of those undergoing only postoperative treatment and 37% (n=40) of patients receiving preoperative chemotherapy also received radiation therapy.

The median overall survival across all patients improved from 4.0 (CI 3.9–4.2) to 4.2 (4.0–4.4) months (p < 0.001). Table 2 summarises the overall survival amongst treatment groups. The Kaplan–Meier survival plot for the radical surgery group comparing 2000–2008 and 2009–2016 appears in
In the radical surgery group, patients receiving only preoperative treatment (n=23) versus pre- and postoperative treatment (n=86) revealed overall survival of 25 (CI 12–39) versus 36 (CI 30–41) months ($p = 0.158$).

In the non-surgical group, we found a minor improvement in the median survival from 3.1 months (CI 3.0–3.3) to 3.3 months (CI 3.2–3.5) ($p < 0.001$). In the no-surgery group, the median survival for patients receiving oncological treatments (n=2324) versus patients who did not receive treatment (n=10352) was 9.2 (CI 8.8–9.6) versus 2.4 (CI 2.3–2.5) months ($p < 0.001$).

Cox regression analysis of effects of clinical parameters on overall survival in patients undergoing radical resection is presented in Table 3. Multivariate analysis was adjusted for age, sex, Charlson comorbidity index, catchment area and operation type. After adjustments, the improvement in survival over time between the inspected time periods 2000–2008 and 2009–2016 was clearly observable (HR 0.68, $p < 0.001$), as well as the initial effect of postoperative adjuvant treatment (HR 0.74, $p = 0.027$) and perioperative adjuvant treatment (HR 0.52, $p = 0.016$). Only 21 patients received solely neoadjuvant treatment, and it did not reach significance. Patients treated in the Helsinki catchment area had better survival compared to the other catchment areas.
4. Discussion

In this nationwide longitudinal study of 14,712 pancreatic cancer patients over 17 years, survival improved, particularly amongst patients undergoing radical surgery. Although the proportion of patients who underwent diagnostic surgery decreased, possibly indicating a better preoperative evaluation and the improved detection of non-resectable disease, the national radical resection rate remained steady at 8%. Low resection rate may indicate stricter patient selection, supported by our results of good survival outcomes. Although the excluded proportion of patients diagnosed post-mortem decreased from 2000–2008 to 2009–2016 the size of the cohort was still substantial. Reported resection rates in the US and other European countries range from 8% to 21% in population-based studies.[11,24–26] Finland has a comparably high incidence for pancreatic cancer which might indicate a better coverage of palliative-treated patients in registers compared to population-based registries in other.[7–9] However, trends towards increasing resection rates have been reported in population-based studies in the US, Denmark, the Netherlands and in France yet, no increase was observed in Belgium, Norway, Slovenia or Estonia.[11,24,26] In another Finnish study, the resection rate reportedly varied between the 21 healthcare districts ranging from 7.7% to 17.9% in 2003 and 2008.[5] In that study, patients were selected from the Finnish cancer registry, but many were excluded based on missing patient records possibly explaining higher observed resection rates. Regional differences in the treatment of pancreatic cancer in Finland were also observed in our study as patients treated in Helsinki catchment area had a survival advantage in the multivariable analysis. In this catchment area, all pancreatic surgery is performed in a single high-volume centre, the Helsinki University Hospital, in recent years.

Increased rates of both preoperative and postoperative oncological treatments are a potential explanation for improved survival amongst those undergoing radical surgery. However, patients diagnosed in 2009 – 2016 had a significant independent survival advantage in the multivariate analysis. Patients who received postoperative oncological treatment in addition to preoperative
treatment exhibited promising survival rates in our study although this may have been influenced by a selection bias. In a recent retrospective cohort study adjuvant therapy improved survival after neoadjuvant treatment only in patients who had a node positive disease.[27] Neoadjuvant therapy has been reported to carry a survival advantage compared to upfront surgery particularly for higher stage and grade-three tumours.[14,28,29] In the US, the neoadjuvant therapy rate for patients with stage I or II disease reached 7.5% overall, which increased from 4.3% to 17% between 1998 and 2011.[30]

An increased rate of oncological therapy in the no-surgery group most likely explains the minor improvements to survival. Van der Geest reported similar overall survival amongst palliative patients in the Netherlands, reporting an overall survival of 7 weeks in untreated patients and 25 weeks in patients receiving chemotherapy.[31] Increasing rates of oncological treatments for palliative patients were reported in the European Union. Specifically, Nienhuijs et al. reported an increase in the palliative chemotherapy rates amongst nonsurgical patients from 5% to 19% in the Netherlands.[11] In another nationwide Dutch study, systemic palliative therapy doubled between 2005 and 2013.[31] In a smaller French register study from the Finistère Area, the palliative chemotherapy rate was much higher at 45.6%.[26]

The strengths of this study include its reliance on a comprehensive long-term nationwide dataset for pancreatic cancer patients which combined information from oncological and surgical treatments. Furthermore, we relied on a large sample size with excellent coverage of the Finnish population. Finally, our data were collected from high-quality registers.[1,2]

The limitations of this study include the secondary nature of register data. A substantial proportion of cases were diagnosed post-mortem and were removed from further analysis since duration of survival is unknown. Further, exclusion of autopsy and death certificate only cases is recommended in data quality control for cancer survival studies.[23] The rates for patients receiving oncological treatments were especially low in the early 2000s. Comparing the oncological data of the local
register of Helsinki University Central Hospital area and HILMO registry, we found a partial incompleteness of the oncological data in the HILMO register. However, across all treatment groups, survival associated with oncological therapy data, whilst treatment group proportions compared favourable to existing literature. In the multivariate analysis, adjuvant therapy that was started more than 6 months after the radical operation was deemed palliative. We acknowledge that this might include some patients who had a recurrent disease diagnosed already, but it’s impossible to distinguish definitely curative-intent and palliative oncological treatment from the data. Some patients did not have histological confirmation so false diagnoses might be included. Disease stage corresponding to the Union for International Cancer Control TNM Classification of Malignant Tumors was not available from the Finnish Cancer Register data. Concomitant vascular procedures could not be identified because of lack of systematic coding. Follow-up data were available from Statistics Finland until the end of 2018 and, thus, some patients had a shorter follow-up period.
5. Conclusions

In Finland, survival amongst pancreatic cancer patients, particularly those who underwent radical surgery, improved during the 2000 to 2016. Although the proportion of patients undergoing diagnostic surgery decreased, we found no increase in the radical intent resection rate. Thus, the improvement in survival is likely due to the advancements in the oncological treatments. Prognosis associated with metastasised disease remains poor.

Acknowledgments: Thanks to Vanessa Fuller for proofreading the article.

Funding: This work was supported by the Finnish Cancer Society (HS, CH), the Helsinki University Hospital Research Fund (CH, PP, HS) and the Sigrid Juselius Foundation (CH, HS). None of the funders participated in the study.

Declaration of Interest: None.
Table 1. Surgical and oncological treatments among Finnish pancreatic cancer patients in 2000–2008 and 2009–2016.

| Surgery          | Oncological treatment | 2000-2008 | 2009-2016 | p*** |
|------------------|-----------------------|-----------|-----------|------|
|                  |                       | N (%)*    | Age**     | n (%)| Age |      |
| Radical          |                       |           |           |      |     |      |
| Perioperative    |                       | 545 (8)   | 66        | 637  (8) | 67  | 1.000 |
| Only preoperative|                       | 10 (2)    | 63        | 76   (12) | 65  | <0.001 |
| Only postoperative|                      | 14 (3)    | 64        | 9    (1) | 66  | 1.000 |
| None             |                       | 138 (25)  | 64        | 300  (47) | 67  | <0.001 |
| Only postoperative|                      | 383 (70)  | 67        | 252  (40) | 67  | <0.001 |
| Diagnostic       |                       |           |           |      |     |      |
| Preoperative     |                       | 545 (8)   | 66        | 309  (4) | 68  | <0.001 |
| Only postoperative|                      | 9 (2)     | 60        | 23   (7) | 64  | 0.423 |
| None             |                       | 122 (22)  | 64        | 109  (35) | 67  | 0.234 |
| None             |                       | 414 (76)  | 67        | 177  (57) | 68  | <0.001 |
| None             |                       | 6702 (84) | 74        | 8010 (88) | 74  | <0.001 |
| Any              |                       | 555 (10)  | 64        | 1769 (25) | 68  | <0.001 |
| None             |                       | 5057 (90) | 75        | 5295 (75) | 77  | <0.001 |

*percentage within each group, **median age, *** the change in treatment group proportion 2000-2008 vs 2009-2016.
Table 2. Overall survival among Finnish pancreatic cancer patients diagnosed in 2000–2008 and 2009–2016 grouped by surgical and oncological care received.

| Surgery | Oncological treatment | 2000-08 Survival 1y | 3y | 5y | Mdn (95% CI) | 2009-16 Survival 1y | 3y | 5y | Mdn (95% CI) | p* |
|---------|----------------------|---------------------|----|----|--------------|---------------------|----|----|--------------|----|
| Radical |                      | 0.68                | 0.27 | 0.16 | 20 (18-22) | 0.79                | 0.39 | 0.26 | 28 (25-31) | <0.001 |
|         | Perioperative         | 0.90                | 0.40 | 0.30 | 16 (0-45)  | 0.91                | 0.51 | 0.31 | 36 (30-42) | 1.000 |
|         | Only preoperative     | 0.79                | 0.36 | 0.36 | 31 (24-37) | 0.67                | 0.11 | 0.11 | 20 (31-41) | 1.000 |
|         | Only postoperative    | 0.83                | 0.38 | 0.16 | 30 (25-34) | 0.87                | 0.44 | 0.29 | 31 (26-35) | 0.234 |
|         | None                 | 0.65                | 0.24 | 0.16 | 17 (15-20) | 0.71                | 0.33 | 0.23 | 22 (16-24) | 0.139 |
| Diagnostic |                      | 0.33                | 0.03 | 0.01 | 8 (8-9)     | 0.35                | 0.03 | 0.02 | 9 (8-10)   | 0.105 |
|         | Preoperative          | 0.78                | 0.00 | 0.00 | 15 (14-16) | 0.74                | 0.04 | 0.00 | 17 (13-20) | 1.000 |
|         | Only postoperative    | 0.52                | 0.06 | 0.03 | 12 (11-13) | 0.45                | 0.06 | 0.04 | 12 (10-12) | 1.000 |
|         | None                 | 0.27                | 0.02 | 0.01 | 7 (6-8)     | 0.25                | 0.02 | 0.01 | 7 (6-8)    | 1.000 |
| None    |                      | 0.13                | 0.03 | 0.02 | 3 (3-3)     | 0.17                | 0.05 | 0.03 | 3 (3-3)    | <0.001 |
|         | Any                  | 0.40                | 0.10 | 0.05 | 10 (9-11)   | 0.37                | 0.09 | 0.05 | 9 (9-9)    | 1.000 |
|         | None                 | 0.13                | 0.03 | 0.02 | 3 (3-3)     | 0.13                | 0.04 | 0.03 | 2 (2-2)    | 0.020 |

Abbreviations: y, year; Mdn, median in months; *Log-rank test P value for 2000–2008 vs 2009–2016
Table 3. Multivariable analysis of effects of clinical parameters on overall survival in pancreatic cancer patients undergoing radical resection

| Parameter                  | Univariate |                |                |                | Multivariate |                |                |                |
|----------------------------|------------|----------------|----------------|----------------|--------------|----------------|----------------|----------------|
|                            |            | 95% CI         |                |                |              | 95% CI         |                |                |
|                            |            | HR lower       | upper          | p              |              | HR lower       | upper          | p              |
| Age at diagnosis           |            |                |                |                |              |                |                |                |
| Years                      | 1.02       | 1.01           | 1.02           | <0.001         |              | 1.02           | 1.01           | 1.02           | <0.001         |
| Gender                     |            |                |                |                |              |                |                |                |
| Male                       | 1.00       |                |                |                |              | 1.00           |                |                |
| Female                     | 1.03       | 0.90           | 1.18           | 0.705          |              | 1.02           | 0.89           | 1.18           | 0.745          |
| CCI                        |            |                |                |                |              |                |                |                |
| 0                          | 1.00       |                |                |                |              | 1.00           |                |                |
| 1                          | 0.94       | 0.78           | 1.12           | 0.475          |              | 0.93           | 0.77           | 1.12           | 0.436          |
| 2                          | 0.93       | 0.75           | 1.14           | 0.457          |              | 0.91           | 0.74           | 1.13           | 0.384          |
| 3 or more                  | 1.13       | 0.89           | 1.45           | 0.319          |              | 1.14           | 0.88           | 1.47           | 0.317          |
| Time of diagnosis          |            |                |                |                |              |                |                |                |
| 2000 – 2008                | 1.00       |                |                |                |              | 1.00           |                |                |
| 2009 – 2016                | 0.68       | 0.60           | 0.78           | <0.001         |              | 0.68           | 0.58           | 0.80           | <0.001         |
| Catchment area             |            |                |                |                |              |                |                |                |
| Helsinki                   | 1.00       |                |                |                |              | 1.00           |                |                |
| Turku                      | 1.46       | 1.19           | 1.81           | <0.001         |              | 1.53           | 1.23           | 1.90           | <0.001         |
| Tampere                    | 1.33       | 1.09           | 1.63           | 0.005          |              | 1.35           | 1.09           | 1.67           | 0.006          |
| Kuopio                     | 1.58       | 1.31           | 1.90           | <0.001         |              | 1.53           | 1.24           | 1.88           | <0.001         |
| Oulu                       | 1.37       | 1.09           | 1.73           | 0.007          |              | 1.39           | 1.10           | 1.77           | 0.007          |
| Surgery                    |            |                |                |                |              |                |                |                |
| PD                         | 1.00       |                |                |                |              | 1.00           |                |                |
| DPR                        | 0.72       | 0.58           | 0.90           | 0.004          |              | 0.79           | 0.63           | 0.99           | 0.039          |
| TP                         | 1.22       | 0.92           | 1.63           | 0.169          |              | 1.35           | 1.01           | 1.82           | 0.043          |
| Other                      | 1.03       | 0.62           | 1.73           | 0.897          |              | 0.98           | 0.59           | 1.66           | 0.951          |
| Oncological treatment      |            |                |                |                |              |                |                |                |
| None                       | 1.00       |                |                |                |              | 1.00           |                |                |
| Only neoadjuvant           | 0.96       | 0.59           | 1.56           | 0.866          |              | 1.21           | 0.74           | 1.98           | 0.458          |
| Only adjuvant              | 0.60       | 0.46           | 0.78           | <0.001         |              | 0.74           | 0.56           | 0.97           | 0.027          |
| Time dependent*            | 1.02       | 1.01           | 1.02           | 0.002          |              | 1.02           | 1.01           | 1.03           | 0.001          |
| Perioperative              | 0.34       | 0.20           | 0.57           | <0.001         |              | 0.52           | 0.30           | 0.89           | 0.016          |
| Time dependent*            | 1.03       | 1.01           | 1.04           | 0.001          |              | 1.03           | 1.01           | 1.04           | 0.001          |

HR = Hazard ratio, CI = confidence interval, CCI = Charlson Comorbidity Index, PD = Pancreaticoduodenectomy, DPR = Distal pancreatic resection, TP = Total pancreatectomy

* Time dependent correction term per month
Fig. 1. Comparison of overall survival among radical surgery pancreatic cancer patients diagnosed in 2000–2008 and 2009–2016 in Finland.

No. at risk
2000-2008  545  493  380  296  239
2009-2016  637  598  515  429  357
[1] Sund R. Quality of the Finnish Hospital Discharge Register: A systematic review. Scand J Public Health 2012;40:505–15. https://doi.org/10.1177/1403494812456637.

[2] Pitkäniemi J, Malila N, Virtanen A, Degerlund H, Heikkinen S SK. Cancer in Finland 2018. Cancer Society of Finland. Publication No. 94, Helsinki n.d.

[3] Leinonen MK, Miettinen J, Heikkinen S, Pitkäniemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer 2017;77:31–9. https://doi.org/10.1016/j.ejca.2017.02.017.

[4] Gooiker GA, Lemmens VEPP, Besselink MG, Busch OR, Bonsing BA, Molenaar IQ, et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg 2014;101:1000–5. https://doi.org/10.1002/bjs.9468.

[5] Ahola R, Hölsä H, Kiskola S, Ojala P, Pirttilä A, Sand J, et al. Access to radical resections of pancreatic cancer is region-dependent despite the public healthcare system in Finland. J Epidemiol Community Health 2018;72:803–8. https://doi.org/10.1136/jech-2017-210187.

[6] Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–75. https://doi.org/10.1016/S0140-6736(17)33326-3.

[7] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. https://doi.org/10.3322/caac.21262.

[8] Cancer statistics. n.d.;310. https://doi.org/10.1001/jama.2013.5289.

[9] Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, et al. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J Gastrointest Cancer 2015;46:201–11. https://doi.org/10.1007/s12029-015-9724-1.
[10] van der Geest LGM, Lemmens VEPP, de Hingh IHJT, van Laarhoven CJHM, Bollen TL, Nio CY, et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg 2017;104:1568–77. https://doi.org/10.1002/bjs.10602.

[11] Nienhuijjs SW, Van Den Akker SA, De Vries E, De Hingh IH, Visser O, Lemmens VE. Nationwide improvement of only short-term survival after resection for pancreatic cancer in the netherlands. Pancreas 2012;41:1063–6. https://doi.org/10.1097/MPA.0b013e31824c3dbf.

[12] Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin 2013;63:318–48. https://doi.org/10.3322/caac.21190.

[13] Gillen S, Schuster T, Büschenfelde CM Zum, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:1–15. https://doi.org/10.1371/journal.pmed.1000267.

[14] Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 2020;JCO.19.02274. https://doi.org/10.1200/jco.19.02274.

[15] Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerA Randomized Controlled Trial. JAMA 2007;297:267–77. https://doi.org/10.1001/jama.297.3.267.

[16] Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, et al. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surg (United States) 2019;166:277–85. https://doi.org/10.1016/j.surg.2019.05.010.

[17] Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological Benefits of Neoadjuvant
Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg 2018;268:215–22. https://doi.org/10.1097/SLA.0000000000002705.

[18] Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surg (United States) 2016;159:893–900. https://doi.org/10.1016/j.surg.2015.09.018.

[19] Lunkka P, Malila N, Rynänen H, Heikkinen S, Sallinen V, Koskenvuo L. Accuracy of Finnish Cancer Registry colorectal cancer data: a comparison between registry data and clinical records. Scand J Gastroenterol 2021;56:247–51. https://doi.org/10.1080/00365521.2020.1867893.

[20] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8.

[21] Quan H, Sundararajan V, Halfon P, Fong A. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43.

[22] Pylväläinen J, Talala K, Murtola T, Taari K, Raitanen J, Tammela TL, et al. Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time. Clin Epidemiol 2019;11:923–32. https://doi.org/10.2147/CLEP.S218697.

[23] Li R, Abela L, Moore J, Woods LM, Nur U, Rachet B, et al. Control of data quality for population-based cancer survival analysis. Cancer Epidemiol 2014;38:314–20. https://doi.org/10.1016/j.canep.2014.02.013.

[24] Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, Van Der Geest L, et al. Resection of pancreatic cancer in Europe and USA: An international large-scale study highlighting large
variations. Gut 2019;68:130–9. https://doi.org/10.1136/gutjnl-2017-314828.

[25] Exarchakou A, Papacleovoulou G, Rous B, Magadi W, Rachet B, Neoptolemos JP, et al.
Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in
England, 2000 to 2014: A population-based study. Pancreatology 2020.
https://doi.org/10.1016/j.pan.2020.01.012.

[26] Arnachellum RP, Cariou M, Nousbaum JB, Jezequel J, Le Reste JY, Robaszkiewicz M.
Pancreatic Adenocarcinoma in the Finistère Area, France, between 2002 and 2011 (1002
Cases): Population Characteristics, Treatment and Survival. Pancreas 2016;45:953–60.
https://doi.org/10.1097/MPA.0000000000000594.

[27] Van Roessel S, Van Veldhuisen E, Klompmaker S, Janssen QP, Abu Hilal M, Alseidi A, et al.
Evaluation of Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer after
Neoadjuvant FOLFIRINOX Treatment. JAMA Oncol 2020;6:1733–40.
https://doi.org/10.1001/jamaoncol.2020.3537.

[28] de Geus SWL, Eskander MF, Bliss LA, Kasumova GG, Ng SC, Callery MP, et al. Neoadjuvant
therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide
propensity score matched analysis. Surg (United States) 2017;161:592–601.
https://doi.org/10.1016/j.surg.2016.08.040.

[29] Nurmi A, Mustonen H, Parviainen H, Peltola K, Haglund C, Seppänen H. Neoadjuvant therapy
offers longer survival than upfront surgery for poorly differentiated and higher stage
pancreatic cancer. Acta Oncol (Madr) 2018;57:799–806.
https://doi.org/10.1080/0284186X.2017.1415458.

[30] Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG, Roman SA, et al. Nationwide
trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis
of 18 243 patients. J Surg Oncol 2017;116:127–32. https://doi.org/10.1002/jso.24630.
[31] van der Geest LGM, Haj Mohammad N, Besselink MGH, Lemmens VEPP, Portielje JEA, van Laarhoven HWM, et al. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Med 2017;6:2840–9.

https://doi.org/10.1002/cam4.1240.
Declaration of interests

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: